Update on emerging treatments for chronic myeloid leukemia
Introduction: As survival of patients with chronic myeloid leukemia (CML) is dramatically
improved over time, the prevalence of the disease is steadily increasing. At this moment, five …
improved over time, the prevalence of the disease is steadily increasing. At this moment, five …
New approaches and treatment combinations for the management of chronic myeloid leukemia
PE Westerweel, PAW Te Boekhorst, MD Levin… - Frontiers in …, 2019 - frontiersin.org
Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is
effective in many patients, but is not curative and frequently limited by intolerance or …
effective in many patients, but is not curative and frequently limited by intolerance or …
First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI
G Saglio, E Jabbour - Leukemia & lymphoma, 2018 - Taylor & Francis
Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1
tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line …
tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line …
Management of chronic myeloid leukemia in 2023–common ground and common sense
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood cancer …, 2023 - nature.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK …
Management of chronic myeloid leukaemia (CML) has recently undergone dramatic
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
A Hochhaus, J Wang, DW Kim, DDH Kim… - … England Journal of …, 2024 - Mass Medical Soc
Background Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term
therapy with high efficacy and safety. Asciminib, a BCR:: ABL1 inhibitor specifically targeting …
therapy with high efficacy and safety. Asciminib, a BCR:: ABL1 inhibitor specifically targeting …
Chronic myeloid leukemia: first‐line drug of choice
E Jabbour - American journal of hematology, 2016 - Wiley Online Library
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …
Chronic myelogenous leukemia
H Kantarjian, E Jabbour, S O'Brien - Molecular Hematology, 2024 - Wiley Online Library
This chapter summarizes our knowledge regarding the molecular biology of chronic myeloid
leukemia (CML) and its treatment modalities using the breakpoint cluster region‐v‐abl …
leukemia (CML) and its treatment modalities using the breakpoint cluster region‐v‐abl …
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase
E Jabbour, JH Lipton - Clinical Lymphoma Myeloma and Leukemia, 2013 - Elsevier
Background The characteristic expression of the constitutively active oncoprotein, BCR-ABL
tyrosine kinase, in chronic myeloid leukemia (CML) was the basis for the development of …
tyrosine kinase, in chronic myeloid leukemia (CML) was the basis for the development of …
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia
S O'Brien, E Berman, JO Moore, J Pinilla-Ibarz… - Journal of the National …, 2011 - jnccn.org
The advent of imatinib has dramatically improved outcomes in patients with chronic
myelogenous leukemia (CML). It has become the standard of care for all patients with newly …
myelogenous leukemia (CML). It has become the standard of care for all patients with newly …